Why the study?
Does c-Cbl-associated protein (CAP) protect against mortality and heart failure in CVB3-mediated myocarditis in mice?
Does c-Cbl-associated protein (CAP) protect against mortality and heart failure in CVB3-mediated myocarditis in mice?
CAP plays a novel protective role in viral myocarditis by stabilizing antiviral type I interferon production and reducing excessive cytotoxic responses.
Answers are grounded in this paper and cite their sources.
CAP modulation remains preclinical in myocarditis; leaves open translation to human viral heart disease therapies.
c-Cbl-associated protein (CAP), also called Sorbs1 or ponsin, has been described as an essential adapter protein in the insulin-signalling pathway. Here, we describe for the first time a unique protective role for CAP in viral myocarditis. Mortality and heart failure development were increased in CAP(-/-) mice compared to CAP(+/+) littermates after Coxsackievirus (CVB3) infection. Mechanistically, CAP protected from tissue apoptosis because of reduced CD8(+) T and natural killer cell cytotoxicity. Despite reduced cytotoxic elimination of CVB3-infected cells in CAP(+/+) hearts, however, CAP enhanced interferon regulatory factor 3 (IRF3)-dependent antiviral type I interferon production and decreased viral proliferation in vitro by binding to the cytoplasmic RIG-I-like receptor melanoma differentiation-associated protein 5 (MDA5). Taken together, these findings reveal a novel modulatory role for CAP in the heart as a key protein stabilizing antiviral type I interferon production, while protecting from excessive cytotoxic responses. Our study will help to define future strategies to develop treatments to limit detrimental responses during viral heart inflammation.
No takes yet. Share an insight, caveat, or question.
Valaperti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: